Oxaliplatin is a third-generation
platinum drug and is widely used as a first-line
therapy for the treatment of
colorectal cancer (CRC). However, a large number of patients receiving
oxaliplatin develop dose-limiting
painful neuropathy. Here, we report that αO-
conotoxin GeXIVA[1,2], a highly potent and selective antagonist of the α9α10
nicotinic acetylcholine receptor (nAChR) subtype, can relieve and reverse
oxaliplatin-induced mechanical and cold
allodynia after single and repeated intramuscular (IM)
injections in rats. Treatments were started at 4 days post
oxaliplatin injection when
neuropathic pain emerged and continued for 8 and 16 days. Cold score and mechanical paw withdrawal threshold (PWT) were detected by the
acetone test and von Frey test respectively.
GeXIVA[1,2] significantly relieved mechanical and cold
allodynia in
oxaliplatin-treated rats after a single injection. After repeated treatments,
GeXIVA[1,2] produced a cumulative
analgesic effect without tolerance and promoted recovery from
neuropathic pain. Moreover, the long lasting
analgesic effect of
GeXIVA[1,2] on
mechanical allodynia continued until day 10 after the termination of the 16-day repeated treatment procedure. On the contrary,
GeXIVA[1,2] did not affect acute mechanical and thermal
pain behaviors in normal rats after repeated
injections detected by the von Frey test and tail flick test.
GeXIVA[1,2] had no influence on rat hind limb grip strength and
body weight after repeated treatments. These results indicate that αO-
conotoxin GeXIVA[1,2] could provide a novel strategy to treat
chemotherapy-induced
neuropathic pain.